How to Reconstitute TB-500: Syringe Selection and Needle Gauge

What Is TB-500 and Why Does Reconstitution Technique Matter?

TB-500 is a synthetic analogue of thymosin beta-4, a 43-amino-acid peptide found at high concentrations in platelets, wound fluid, and multiple human tissues. The commercially available research form is typically supplied as lyophilized (freeze-dried) powder that must be reconstituted before injection. Handling errors at this step, such as using tap water instead of bacteriostatic water, choosing the wrong syringe, or shaking the vial, can degrade the peptide irreversibly.

The Stability Context

Peptides in lyophilized form are stable at room temperature for extended periods, but once reconstituted they are vulnerable to agitation, temperature, and microbial contamination. USP <797> guidelines for compounded sterile preparations require beyond-use dates (BUDs) and specific handling practices to maintain sterility and potency of injectable preparations. [1] Bacteriostatic water, which contains 0.9% benzyl alcohol as a preservative, extends the usable window of a reconstituted peptide vial compared with sterile water for injection.

Why Syringe Choice Is Not Optional

Choosing the wrong syringe introduces two concrete problems. First, large-bore needles cause unnecessary tissue trauma and pain with repeated subcutaneous injections. Second, a syringe with low graduation resolution, such as a 3 mL syringe marked in 0.1 mL increments, makes it nearly impossible to measure a dose like 0.25 mL accurately. A 1 mL insulin syringe marked in 0.01 mL increments gives you dose accuracy to within roughly 0.01 mL, which at a standard reconstitution volume translates to less than 0.05 mg variance per injection.

Bacteriostatic Water: The Only Correct Diluent for TB-500

Bacteriostatic water for injection (BWFI), not normal saline, not tap water, and not plain sterile water, is the standard diluent for peptide reconstitution in clinical compounding practice.

Why Bacteriostatic Water?

BWFI contains 0.9% benzyl alcohol, which inhibits microbial growth between uses. Because a single 2 mg or 5 mg TB-500 vial typically provides multiple doses drawn over days to weeks, multi-use microbial safety is essential. Sterile water for injection carries no preservative and is therefore unsuitable for multi-draw vials; USP <1> monographs specify benzyl alcohol-preserved water precisely for this multi-dose context. [2]

FDA-registered bacteriostatic water for injection is available in 30 mL multi-dose vials from multiple compounders and pharmaceutical suppliers. The benzyl alcohol concentration of 0.9% w/v is well below the 99 mg/kg/day threshold associated with "gasping syndrome" in neonates, but practitioners should note that BWFI is contraindicated in newborns per FDA labeling. [3]

Volume Calculation for a 2 mg Vial

Adding 1 mL of BWFI to a 2 mg vial yields a concentration of 2,000 mcg/mL (2 mg/mL). At that concentration, a 250 mcg dose equals 0.125 mL, which falls neatly on the 12.5-unit mark of a U-100 insulin syringe. Adding 2 mL to the same vial yields 1 mg/mL, so a 250 mcg dose becomes 0.25 mL, which falls on the 25-unit mark. The 2 mL reconstitution is easier to measure accurately for most users.

| Vial Size | BWFI Added | Concentration | 2.5 mg Dose Volume | |-----------|-----------|---------------|-------------------| | 2 mg | 1 mL | 2 mg/mL | 0.125 mL (12.5 IU) | | 2 mg | 2 mL | 1 mg/mL | 0.25 mL (25 IU) | | 5 mg | 2 mL | 2.5 mg/mL | 1 mL (100 IU) | | 5 mg | 2.5 mL | 2 mg/mL | 1.25 mL (125 IU) |

Syringe Selection: The 1 mL U-100 Insulin Syringe

The 1 mL U-100 insulin syringe is the clinical standard for subcutaneous peptide injections. Each unit mark on a U-100 syringe represents 0.01 mL. That graduation resolution is the reason peptide protocols almost universally specify insulin syringes rather than standard 3 mL or 5 mL draw syringes.

Reading the Markings Correctly

A U-100 insulin syringe displays markings in "units" where 100 units equals 1 mL. So:

• 10 units = 0.10 mL
• 25 units = 0.25 mL
• 50 units = 0.50 mL

No conversion arithmetic is needed once you have calculated the dose in mL from your reconstitution math. A 0.25 mL dose is simply drawn to the 25-unit line.

0.5 mL vs. 1 mL Syringes

For doses below 0.5 mL, a 0.5 mL insulin syringe (50-unit) provides even finer relative resolution and is easier to hold steady during subcutaneous injection. Doses above 0.5 mL require the full 1 mL barrel. Choose based on your calculated injection volume, not habit.

Never Use a 3 mL Syringe for Peptide Dosing

A standard 3 mL Luer-lock syringe has graduation marks at 0.1 mL intervals. Measuring 0.13 mL in a 3 mL syringe introduces an error of up to ±50%, which at peptide doses translates into meaningful over- or underdosing. The insulin syringe eliminates this problem entirely.

Needle Gauge: Two Needles, Two Jobs

Reconstituting TB-500 and injecting TB-500 are two separate tasks that benefit from two different needle gauges. Using the same thin 29-gauge needle for both adds unnecessary time and risks coring the rubber septum.

Reconstitution Needle: 21 to 23 Gauge

For drawing bacteriostatic water from the BWFI vial and injecting it slowly into the TB-500 vial, a 21-gauge or 23-gauge 1-inch needle is appropriate. The larger bore pulls liquid quickly without excessive negative pressure and allows you to direct the stream of BWFI down the side of the TB-500 vial (rather than onto the lyophilized powder cake directly, which causes foaming and potential denaturation).

After the peptide is dissolved, discard this draw needle and attach a fresh injection needle before administering.

Injection Needle: 27 to 29 Gauge, 0.5 Inch

For subcutaneous injection, the accepted range is 27-gauge to 29-gauge at 0.5-inch (12.7 mm) length. A 2019 review of subcutaneous injection technique published in a clinical nursing context confirmed that needles of 25 to 31 gauge at 4 to 8 mm effectively reach subcutaneous tissue in adults across a broad BMI range when a 45-degree insertion angle is used. [4]

The 28-gauge needle is a practical sweet spot: finer than 27-gauge (so less pain), but it draws reconstituted solution without the slow fill times of a 31-gauge. Many practitioners prefer 29-gauge as a compromise between flow rate and patient comfort.

Intramuscular Injection: When Is It Used?

Some TB-500 protocols specify intramuscular (IM) injection for faster absorption to a target area. IM injections use a longer needle, typically 1 inch to 1.5 inch, at 22 to 25 gauge. Injection sites for IM include the ventrogluteal or vastus lateralis muscle. IM administration is less common for TB-500 than subcutaneous dosing, and the evidence base for preferring one route over the other in humans is limited. Most compounding protocols default to subcutaneous.

Step-by-Step Reconstitution Protocol

Precision technique prevents contamination, degradation, and dosing errors. Follow these steps in order.

Step 1: Gather Supplies

You need: one TB-500 lyophilized vial, one 30 mL vial of BWFI, two alcohol swabs, one 21 to 23 gauge draw needle attached to a 1 mL or 3 mL syringe (for the reconstitution draw only), and one capped 27 to 29 gauge 1 mL insulin syringe for the actual injection.

Step 2: Sanitize Both Vial Septa

Wipe the rubber septum of the BWFI vial and the TB-500 vial with separate alcohol swabs. Allow 30 seconds of air-dry time. Wet alcohol on the septum can carry contamination into the vial on the needle.

Step 3: Draw the Bacteriostatic Water

Insert the 21 to 23 gauge draw needle into the BWFI vial. Pull back the plunger to draw your target volume, typically 1 to 2.5 mL depending on your concentration goal (see the table above). Invert the vial if needed to avoid drawing air.

Step 4: Inject BWFI Into the Peptide Vial Slowly

Insert the draw needle through the TB-500 septum at an angle. Direct the stream of BWFI down the inner glass wall of the vial rather than straight onto the powder. Inject slowly over 10 to 15 seconds. This prevents foaming, which can denature the peptide. Peptide denaturation from aggressive reconstitution has been documented in stability studies of similar therapeutic peptides. [5]

Step 5: Swirl, Do Not Shake

After injection, gently swirl the vial between your palms for 20 to 30 seconds. Do not vortex or shake. The solution should become clear. Slight cloudiness may indicate incomplete dissolution; swirl again and allow 60 seconds before re-checking. Persistent cloudiness suggests contamination or degradation.

Step 6: Switch to the Injection Needle

Remove the draw needle. Attach the 27 to 29 gauge 0.5-inch insulin syringe needle. Insert it through the sanitized septum and draw your calculated dose volume. Remove any air bubbles by tapping the barrel and gently expressing air before withdrawing the needle.

Step 7: Inject Subcutaneously

Pinch a fold of skin at the injection site (abdomen, lateral thigh, or flank are common). Insert the needle at 45 degrees. Depress the plunger steadily over 3 to 5 seconds. Withdraw and apply light pressure with a dry gauze pad.

Dosing Reference: Common TB-500 Protocols

TB-500 does not have an FDA-approved human dosing indication. The protocols below reflect reported compounding and research-use ranges drawn from published thymosin beta-4 pharmacology data and clinical case observations.

Loading Phase (Weeks 1 to 4)

• Total weekly dose: 4 to 8 mg
• Frequency: 2 to 3 injections per week
• Example: 5 mg vial reconstituted in 2.5 mL BWFI = 2 mg/mL; a 1 mg dose is 0.5 mL drawn to the 50-unit mark on a U-100 syringe

Maintenance Phase (Weeks 5 to 12)

• Total weekly dose: 2 to 2.5 mg
• Frequency: 1 to 2 injections per week
• Example: same 2 mg/mL concentration; a 1.25 mg maintenance dose is 0.625 mL, or 62.5 units on a U-100 syringe

Thymosin beta-4 has demonstrated tissue-protective and repair-associated activity in cardiac, ocular, and dermal injury models. A 2010 study in the Journal of Molecular Medicine showed that systemic thymosin beta-4 administration in mice promoted cardiomyocyte survival and reduced infarct size after myocardial ischemia. [6] Human trials remain limited, and extrapolating animal data to clinical human dosing requires caution.

A 2014 phase II trial (NCT01248949) examined thymosin beta-4 in patients with dry eye syndrome and found the peptide was well-tolerated at topical doses, providing early safety data in humans. [7]

Storage After Reconstitution

Reconstituted TB-500 must be stored at 2 to 8°C (standard refrigerator temperature). Light exposure accelerates peptide degradation; wrap the vial in foil or store it in an opaque container. The beyond-use date for BWFI-reconstituted peptides under USP <797> Category 1 (low-risk, compounded sterile preparation) guidance is generally 14 days at room temperature or 45 days refrigerated, but most practitioners apply a 28-day refrigerated BUD as a conservative and practical standard. [1]

Never freeze a reconstituted peptide vial. Ice crystal formation disrupts the tertiary structure of peptides. The lyophilized powder can be frozen before reconstitution; once you add BWFI, the freezer is off-limits.

Common Reconstitution Errors and How to Avoid Them

Using the Wrong Water

Tap water introduces minerals, chloramines, and bacteria. Sterile water for injection (not bacteriostatic) is safe for single-use vials only. For any peptide that you intend to draw from more than once, BWFI is the correct choice.

Injecting BWFI Too Fast

High-velocity injection creates turbulence that forces the peptide to unfold. Ten to fifteen seconds for a 2 mL injection is slow enough to prevent this.

Reusing Needles

Needle tips dull after one insertion. A dulled needle causes more tissue trauma, increases the chance of septum coring (rubber fragments entering the vial), and raises infection risk. Use a fresh needle for every injection.

Storing Outside the Refrigerator

Leaving reconstituted TB-500 on a counter at 22°C for more than a few hours can measurably reduce potency. Peptide bond hydrolysis in aqueous solution is temperature-dependent; lower temperatures dramatically slow this process. [5]

Not Checking for Particulates

Before each draw, inspect the vial. Any visible particles, color change from clear to yellow or brown, or cloudiness that does not resolve with swirling indicates contamination or degradation. Discard the vial.

Injection Site Rotation

Rotating sites prevents lipohypertrophy, a condition well-documented in insulin-dependent diabetic patients that results from repeated subcutaneous injections in the same location. [8] A practical rotation system divides the abdomen into four quadrants and cycles through them, using each no more than once per week.

Common subcutaneous sites for TB-500:

• Lateral abdomen (2 inches from the navel)
• Lateral thigh (outer third of the quadriceps)
• Flank (love handle area)
• Deltoid fat pad (for small-volume injections only)

IM sites, if that route is chosen, rotate between the ventrogluteal and vastus lateralis muscles.

Regulatory and Safety Context

TB-500 is not FDA-approved as a drug product for human use. In the United States, it is sold as a research chemical. The FDA has placed thymosin beta-4 on the list of "bulk drug substances that may not be used in compounding" under certain interpretations of 503A and 503B pharmacy compounding regulations, though regulatory status has shifted over successive guidance cycles and practitioners should consult current FDA guidance at fda.gov for the most up-to-date position. [9]

The Endocrine Society's clinical practice guidelines for compounded hormones and peptides note that "compounded preparations lack the rigorous pharmacokinetic and safety data required of FDA-approved drugs," a standard that applies equally to peptide research compounds administered off-label. [10]

Practitioners and patients using TB-500 outside an approved clinical trial accept the risk profile of an investigational compound. Baseline bloodwork including complete metabolic panel and CBC before initiation, and at 8-week intervals during use, represents a reasonable minimum monitoring strategy.